Ms Anne O’Driscoll and Dr Martin Fahy to Join the Board of FINEOS
FINEOS Corporation, the market-leading provider of group, voluntary and individual core systems for life, accident and health insurance, today announced that Ms Anne O’Driscoll and Dr Martin Fahy have joined the FINEOS Board as Non-Executive Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190507005496/en/
l-r Anne O'Driscoll, Martin Fahy, Michael Kelly, Peter Le Beau, Gilles Biscay, Tom Wall (Photo: Business Wire)
Anne is a chartered accountant and is on the boards of Comminsure insurance, Steadfast Group Limited and Infomedia Limited, as well as MDA National Pty Limited. Anne began her career with PwC in London. She moved to Sydney, Australia, with PwC and then in 1992 she joined IAG insurance, one of Australia’s largest insurers. Following 13 years with IAG Anne moved to Genworth Australia, as CFO. She is well known within the Australian insurance market and has an exemplary track record as a company director.
Martin is currently the CEO of the Association of Superannuation Funds of Australia (ASFA). He was previously a partner at KPMG, where he worked with clients across financial services and other sectors to drive transformational change. From 2007 to 2011, Martin was CEO at the Financial Services Institute of Australasia (FINSIA). Prior to FINSIA, he led strategy and development for the Chartered Institute of Management Accountants (CIMA) in Asia Pacific. Martin holds a PhD from the National University of Ireland, is a former senior Fulbright scholar and has extensive research and policy experience from his time as an academic. He is also an Adjunct Professor at the University of Technology Sydney, where he is also Chair of the Centre for Management and Organisational Studies (CMOS) Advisory Board.
Dr Fahy will be the keynote presenter at the FINEOS APAC Summit, which will be taking place in Sydney on May 23. We are looking forward to his presentation entitled “The Changing Insurance Landscape: Delivering Flawless Execution and Transformation in an Increasingly Regulated World.”
“We are delighted that Anne and Martin have agreed to serve as FINEOS directors and look forward to benefitting from their judgment and insight. Their experience across financial services and IT transformation will add a valuable perspective to our Board” said Peter le Beau, Chairman of the FINEOS Board.
About FINEOS Corporation
FINEOS has over 50 life, accident and health insurance customers globally; including 7 of the top ten carriers in the US and 4 of the top 5 carriers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive carriers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides full end to end core claims, billing and policy administration for group, voluntary and individual business across life, accident and health. The FINEOS Platform includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com.
+ 353 1 639 9700
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gilead Announces Latest Data in Ongoing HIV Cure Research Program23.7.2019 23:00:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses
Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 18:30:00 EEST | Press release
Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu
Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 18:00:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These
Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 18:00:00 EEST | Press release
Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol
Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 17:12:00 EEST | Press release
US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing
Andersen Global Expands into Ghana23.7.2019 16:30:00 EEST | Press release
Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom